

Figure 1:

**Annotated ^1H NMR Spectrum of Compound 1
(annotated numbers denote the assignments).**




Figure 2:

**Annotated ^{13}C NMR Spectrum of Compound 1
(annotated numbers denote the assignments).**




Figure 3:

Annotated ^{19}F NMR Spectrum of Compound 1 (annotated numbers denote the assignments).






Figure 4:**UV-Vis-Spectrum of Compound 1 in Methanol.**

Figure 5:
HPLC chromatogram of Compounds 1 and 2.



Compound 2 Compound 1



Figure 6:**Flowchart of the Preparation of Compounds 1 and 2.**

Figure 7:**A: Crystal Structure of Compound-1-Dibenzoyl-D-tartrate.**

The absolute structure has been determined on the basis of the (2*S*,3*S*)-Dibenzoyl-D-tartrate.

Figure 7:

B: XRPD of Compound-1-Dibenzoyl-D-tartrate.





Figure 8:


Crystal Structure of Compound-2-Dibenzoyl-L-tartrate.



The absolute structure has been determined on the basis of the (2*R*,3*R*)-Dibenzoyl-L-tartrate.

Figure 9:

**Non-sink Dissolution Behavior in FaSSIF of Compound 1
and specific salts thereof.**



Parent batch = Compound 1


Figure 10:**XRPD of Solid Form of Compound 1 Fumarate**


Figure 11**XRPD of Solid Form of Compound 1 Napsylate**


Figure 12**XRPD of Solid Form of Compound 1 Edisylate.**


Figure 13:**XRPD of Solid Form A2 of Compound 1.**


Figure 14:**XRPD of Solid Form A1 of Compound 1.**


Figure 15:**XRPD of Solid Form A3 of Compound 1.**


Figure 16:**XRPD of Solid Form NF9 of Compound 1.**

Figure 17:

XRPD of Solid Form H1 of Compound 1 Hydrate.





Figure 18:**XRPD of Solid Form H2 of Compound 1 Hydrate.**


Figure 19:**XRPD of Solid Form NF19 of Compound 1.**

Figure 20:

**Strong Tumor Growth Inhibition by Irradiation and Concomitant Oral Compound 1
(6 x 5 days, 2 Gy; FaDu SCCHN Tumor Model)**




Figure 21:

***In vivo* evaluation of anti-tumor activity of Compound 1 and comparative ATM inhibitor in combination with olaparib, in HBCx-10 patient-derived triple-negative breast cancer xenograft model**




Figure 22:
DSC heating curve of Form A2 of Compound 1




Figure 23:
TGA heating curve of Form A2 of Compound 1





Figure 24:

DVS water uptake isotherm (25 °C) of Form A2 of Compound 1

**Figure 25:**

DSC heating curve of Form A1 of Compound 1






Figure 26:**TGA heating curve of Form A1 of Compound 1****Figure 27:****DVS water uptake isotherm (25 °C) of Form A3 of Compound 1**

Figure 28:
DSC heating curve of Form H2 of Compound 1




Figure 29:
TGA heating curve form H2 of Compound 1






Figure 30:**DVS water uptake isotherm (25°C) of Form H2 of Compound 1 (hydrate).****Figure 31:****DSC heating curve of Compound 1 Fumarate (Form "NF6")**



Figure 32:**TGA heating curve of Compound 1 Fumarate (Form “NF6”)****Figure 33:****DVS water uptake isotherm (25 °C) of Compound 1 Fumarate (Form “NF6”)**



Figure 34:**DSC heating curve of Compound 1 Napsylate (NF7)****Figure 35:****TGA heating curve of Compound 1 Napsylate (NF7)**



Figure 36:**DVS water uptake isotherm (25 °C) of Compound 1 Napsylate (NF7)****Figure 37:****DSC heating curve of Compound 1 Edisylate (NF8)**



Figure 38:**TGA heating curve of Compound 1 Edisylate (NF8)****Figure 39:****DVS water uptake isotherm (25 °C) of Compound 1 Edisylate (NF8)**



Figure 40:**XRPD of a methanolate of Compound 1 in solid form S1****Figure 41:****XRPD of a hydrate/methanolate of Compound 1 in solid form S2**



Figure 42:**XRPD of a THF solvate of Compound 1 in solid form S3****Figure 43:****XRPD of a dioxane solvate of Compound 1 in solid form NF11**




Figure 44:**XRPD of a chloroform solvate of Compound 1 in solid form NF15****Figure 45:****XRPD of an acetic acid solvate of Compound 1 in solid form NF16**

Figure 46:

XRPD of an acetic acid solvate of Compound 1 in solid form NF18

**Figure 47:**

XRPD of a 1,4-dioxane solvate of Compound 1 in solid form NF29





Figure 48:

XRPD of a dichloromethane solvate of Compound 1 in solid NF32

**Figure 49:**

XRPD of a NMP (N-Methyl-2-pyrrolidon) solvate of Compound 1 in solid NF33






Figure 50:**XRPD of an acetonitrile solvate of Compound 1 in solid form NF35****Figure 51:****XRPD of a 1,4-dioxane solvate of Compound 1 in solid form NF36**

Figure 52:

XRPD of a dimethylacetamide solvate of Compound 1 in solid form NF37

